CNTX Context Therapeutics Inc.
USHealthcareAs of 2026-10-08
Why CNTX matters now
Context Therapeutics Inc. (CNTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.30 with -4.35% on the session and $27.5M in market capitalization; recent performance reads 1-month -70.88% and YTD -57.01%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.7M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -56.5%.
The latest indexable market news headline is "Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.25; recent insider activity includes Lehr Martin A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.15
P/S
0.00
EV/EBITDA
-0.09
DCF Value
$0.67
FCF Yield
-56.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.0%
ROA
-68.3%
ROIC
-82.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.7M | $-0.09 |
| Q4 2025 | $0.00 | $-13.0M | $-0.14 |
| FY 2025 | $0.00 | $-36.1M | $-0.38 |
| Q3 2025 | $0.00 | $-9.7M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.25
Target (Median)
$5.25
Target Range
$4.50 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.61
Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.